OSR (NASDAQ:OSRH) Shares Down 5.5% – Time to Sell?

OSR Holdings, Inc. (NASDAQ:OSRH) shares fell 5.5% during trading on Tuesday . The company traded as low as $0.4253 and last traded at $0.4375. 579,919 shares changed hands during mid-day trading, a decline of 28% from the average daily volume of 803,054 shares. The stock had previously closed at $0.4628.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on OSRH. Weiss Ratings restated a “sell (e+)” rating on shares of OSR in a report on Wednesday, June 24th. Wall Street Zen upgraded OSR from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, OSR has an average rating of “Sell”.

OSR Stock Performance

The stock’s fifty day simple moving average is $0.41 and its 200-day simple moving average is $0.50. The stock has a market cap of $15.37 million, a P/E ratio of -1.33 and a beta of 0.72.

OSR (NASDAQ:OSRH) last announced its earnings results on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter. The business had revenue of $0.48 million for the quarter. OSR had a negative return on equity of 7.24% and a negative net margin of 363.26%.

Institutional Trading of OSR

An institutional investor recently bought a new stake in OSR stock. Susquehanna International Group LLP purchased a new position in OSR Holdings, Inc. (NASDAQ:OSRH) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR as of its most recent filing with the Securities and Exchange Commission (SEC). 55.30% of the stock is currently owned by hedge funds and other institutional investors.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.